PT  - JOURNAL ARTICLE
AU  - Lea A Moukarzel
AU  - Jacqueline Feinberg
AU  - Evan J Levy
AU  - Mario M Leitao, Jr.
TI  - Current and novel mapping substances in gynecologic cancer care
AID  - 10.1136/ijgc-2019-001078
DP  - 2020 Jan 15
TA  - International Journal of Gynecologic Cancer
PG  - ijgc-2019-001078
4099  - http://ijgc.bmj.com/content/early/2020/01/14/ijgc-2019-001078.short
4100  - http://ijgc.bmj.com/content/early/2020/01/14/ijgc-2019-001078.full
AB  - Many tracers have been introduced into current medical practice with the purpose of improving lymphatic mapping techniques, anatomic visualization, and organ/tissue perfusion assessment. Among them, three tracers have dominated the field: indocyanine green, technetium-99m radiocolloid (Tc99m), and blue dye. Tc99m and blue dye are used individually or in combination; however, given particular challenges with these tracers, such as the need for a preoperative procedure by nuclear medicine and cost, other options have been sought. Indocyanine green has proven to be a promising alternative for certain procedures, as it is easy to use and has quick uptake. Its use in the management of gynecologic cancers was first described for sentinel lymph node mapping in cervical cancer, and later for endometrial and vulvar cancers. This review provides an in-depth look at these mapping substances, their uses, and the potential for new discoveries.